Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 11/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 2/20 | 0.41 |
| ▸ | SKP1 | P63208 | 2/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9968521 | 0.89 | CKS1B (0.51) | SMOCKS1BSKP1SKP2 | |
| SCHEMBL9932881 | 0.86 | SMO (0.60) | SMOMEN1KMT2AMKNK1MKNK2 | |
| SCHEMBL9932472 | 0.86 | SMO (0.66) | SMO | |
| SCHEMBL9968423 | 0.85 | SMO (0.47) | SMOMEN1KMT2AMKNK1MKNK2 | |
| SCHEMBL1533965 | 0.84 | MKNK1 (0.54) | SMOMEN1KMT2AMKNK1MKNK2 | |
| SCHEMBL9932312 | 0.82 | SMO (0.48) | SMOMEN1KMT2AFAAHEPHX2 | |
| SCHEMBL9931835 | 0.82 | SMO (0.61) | SMOMEN1KMT2ACKS1BSKP1 | |
| SCHEMBL9932685 | 0.82 | SMO (0.54) | SMO | |
| SCHEMBL9931706 | 0.82 | SMO (0.63) | SMOMEN1KMT2ADRD4GRM2 | |
| SCHEMBL1533944 | 0.82 | SMO (0.48) | SMOMEN1KMT2AMKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | SMO 1/4885MEN1 1168/4885KMT2A 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.